February 13, 2008 Meeting Summary
Sponsored by:
Speakers
Thar Technologies
In the past decade, Supercritical Fluid Chromatography (SFC) has increasingly gained momentum in both the chemical and pharmaceutical industries. The intrinsic low viscosity and high diffusivity of supercritical CO2 has rendered SFC higher separation speeds and efficiency than traditional LC, especially in chiral analysis and purifications. As the analytical philosophy in drug discovery gradually shifts toward generating high-quality and more informative data within a minimal time frame, SFC MS readily lends itself as an attractive complement to the industry-dominating LC MS. This is due to the combination of the high speed and unique selectivity of SFC and the universality, sensitivity, and specificity of MS.
The Role of SFC in Drug Discovery at Merck
Merck, West Point, PA
SFC has become an integral part of Drug Discovery at Merck since the acquisition of the first analytical SFC in the late 1990s. An analytical SFC/MS and mass-directed, semi-preparative SFC has been added to the existing list of SFC instrumentation. This new technology will provide achiral analysis and purification of iterative libraries of compounds in Medicinal Chemistry. We will take a look at the varying roles SFC plays in support of Drug Discovery from Basic Research through Preclinical Development. Both achiral and chiral analysis and related purifications will be examined on large and small scale separations. The benefits of "going green" will be highlighted with an emphasis on real world cost savings provided by the technique.
